Merck's phase 3 KEYNOTE─522 trial of Keytruda meets its OS endpoint in patients with high─risk early─stage triple ...
Merck, known as MSD outside of the United States and Canada, today announced that the phase 3 KEYNOTE-522 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, met its overall survival (OS) endpoint, in combination with chemotherapy as pre-operative ( …